Headache medication and the COVID-19 pandemic

Area of Science:

• Infectious Diseases
• Pharmacology
• Neurology

Background:

• The COVID-19 pandemic has raised concerns regarding potential drug interactions.
• A putative link between Renin-Angiotensin System (RAS) inhibitors, ibuprofen, and increased COVID-19 risk has been proposed.
• Headache management is a common clinical scenario where these drugs are used.

Purpose of the Study:

• To evaluate the safety of continuing RAS inhibitors and ibuprofen for headache treatment during the COVID-19 pandemic.
• To address patient and clinician concerns about potential increased COVID-19 risk associated with these medications.

Main Methods:

• Review of current scientific literature and evidence.
• Discussion of the pharmacological properties of RAS inhibitors and ibuprofen in relation to viral infections.
• Analysis of the risk-benefit profile for headache patients.

Main Results:

• No current evidence supports an increased risk of COVID-19 infection or severity with RAS inhibitors or ibuprofen.
• The benefits of managing headache symptoms with these medications outweigh theoretical risks.

Conclusions:

• Patients with headaches can safely continue treatment with RAS inhibitors and ibuprofen.
• Abandoning effective headache treatment based on unproven concerns is not recommended during the COVID-19 pandemic.